ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
ResMed (NYSE: RMD, ASX: RMD) has launched the AirTouch™ N30i, its first fabric-wrapped CPAP mask. This innovative nasal mask features a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up configuration. The AirTouch N30i combines softness, breathability, and a high-performance seal to deliver exceptional comfort.
In a multi-center study with experienced CPAP users, 92.6% preferred AirTouch N30i for long-term use, and 96.7% rated it appealing or very appealing for its look and feel. The mask incorporates a ComfiSoft™ cushion and fabric-wrapped frame with a fabric seal design coated over silicone. Available in three cushion sizes and two frame sizes, it offers a customized fit. The AirTouch N30i will be available in the U.S. beginning the week of October 28, 2024.
ResMed (NYSE: RMD, ASX: RMD) ha lanciato l'AirTouch™ N30i, la sua prima maschera CPAP avvolta in tessuto. Questa innovativa maschera nasale presenta un design morbido, traspirante e in grado di gestire l'umidità per un comfort ottimale in configurazione con tubo verso l'alto. L'AirTouch N30i combina morbidezza, traspirabilità e una tenuta ad alte prestazioni per garantire un comfort eccezionale.
In uno studio multicentrico con utenti CPAP esperti, il 92,6% ha preferito l'AirTouch N30i per un utilizzo a lungo termine, e il 96,7% l'ha trovata attraente o molto attraente per il suo aspetto e la sensazione al tatto. La maschera incorpora un cuscinetto ComfiSoft™ e un telaio avvolto in tessuto con un design del sigillo in tessuto rivestito in silicone. Disponibile in tre misure di cuscinetto e due misure di telaio, offre una vestibilità personalizzata. L'AirTouch N30i sarà disponibile negli Stati Uniti a partire dalla settimana del 28 ottobre 2024.
ResMed (NYSE: RMD, ASX: RMD) ha lanzado el AirTouch™ N30i, su primera máscara CPAP envuelta en tela. Esta innovadora máscara nasal presenta un diseño suave, transpirable y que absorbe la humedad para un confort óptimo en una configuración con el tubo hacia arriba. El AirTouch N30i combina suavidad, transpirabilidad y un sellado de alto rendimiento para ofrecer un confort excepcional.
En un estudio multicéntrico con usuarios experimentados de CPAP, el 92,6% prefirió el AirTouch N30i para un uso a largo plazo, y el 96,7% lo calificó de atractivo o muy atractivo por su apariencia y sensación. La máscara incorpora un cojín ComfiSoft™ y un marco envuelto en tela con un diseño de sellado de tela recubierto de silicona. Disponible en tres tamaños de cojín y dos tamaños de marco, ofrece un ajuste personalizado. El AirTouch N30i estará disponible en EE. UU. a partir de la semana del 28 de octubre de 2024.
ResMed (NYSE: RMD, ASX: RMD)가 첫 번째 천으로 감싸인 CPAP 마스크인 AirTouch™ N30i를 출시했습니다. 이 혁신적인 비강 마스크는 부드럽고 통기성이 있으며 수분을 흡수하는 디자인을 특징으로 하여 튜브가 위로 향하는 구성에서 최적의 편안함을 제공합니다. AirTouch N30i는 부드러움, 통기성 및 고성능 씰을 결합하여 뛰어난 편안함을 제공합니다.
경험이 많은 CPAP 사용자를 대상으로 한 다수 센터 연구에서 92.6%가 장기 사용을 위해 AirTouch N30i를 선호했습니다. 96.7%는 외관과 느낌에 대해 매력적이거나 매우 매력적이라고 평가했습니다. 이 마스크는 실리콘으로 코팅된 천 씰 디자인을 가진 ComfiSoft™ 쿠션과 천으로 감싼 프레임을 통합합니다. 세 가지 쿠션 크기와 두 가지 프레임 크기로 제공되어 맞춤형 핏을 제공합니다. AirTouch N30i는 2024년 10월 28일 주부터 미국에서 판매될 예정입니다.
ResMed (NYSE: RMD, ASX: RMD) a lancé l'AirTouch™ N30i, son premier masque CPAP enveloppé de tissu. Ce masque nasal innovant présente un design doux, respirant et évacuant l'humidité pour un confort optimal en configuration avec tube vers le haut. L'AirTouch N30i allie douceur, respirabilité et un joint haute performance pour offrir un confort exceptionnel.
Dans une étude multicentrique menée auprès d'utilisateurs CPAP expérimentés, 92,6% ont préféré l'AirTouch N30i pour un usage à long terme, et 96,7% l'ont jugé attrayant ou très attrayant pour son esthétique et sa sensation. Le masque intègre un coussin ComfiSoft™ et un cadre enveloppé de tissu avec un design de joint en tissu revêtu de silicone. Disponible en trois tailles de coussin et deux tailles de cadre, il offre un ajustement personnalisé. L'AirTouch N30i sera disponible aux États-Unis à partir de la semaine du 28 octobre 2024.
ResMed (NYSE: RMD, ASX: RMD) hat die AirTouch™ N30i eingeführt, seine erste CPAP-Maske mit Stoffüberzug. Diese innovative Nasenmaske bietet ein weiches, atmungsaktives und feuchtigkeitsableitendes Design für optimalen Komfort in einer Tubus-oben-Konfiguration. Die AirTouch N30i kombiniert Weichheit, Atmungsaktivität und eine Hochleistungsdichtung, um außergewöhnlichen Komfort zu gewährleisten.
In einer multizentrischen Studie mit erfahrenen CPAP-Nutzern bevorzugten 92,6% die AirTouch N30i für den langfristigen Gebrauch und 96,7% empfanden das Aussehen und das Gefühl der Maske als ansprechend oder sehr ansprechend. Die Maske verfügt über ein ComfiSoft™ Kissen und einen mit Stoff umwickelten Rahmen mit einem über Silikon beschichteten Stoffdichtungsdesign. Sie ist in drei Kissen- und zwei Rahmengrößen erhältlich und bietet eine maßgeschneiderte Passform. Die AirTouch N30i wird ab der Woche vom 28. Oktober 2024 in den USA erhältlich sein.
- Launch of innovative AirTouch™ N30i CPAP mask with fabric-wrapped frame
- 92.6% of experienced CPAP users preferred AirTouch N30i for long-term use in a multi-center study
- 96.7% of users rated AirTouch N30i appealing or very appealing for its look and feel
- Customizable fit with three cushion sizes and two frame sizes
- None.
Insights
The introduction of ResMed's AirTouch N30i CPAP mask represents a significant innovation in sleep apnea treatment. This fabric-wrapped, tube-up nasal mask addresses key patient comfort issues that often lead to non-compliance with CPAP therapy. The ComfiSoft cushion and fabric-coated silicone design aim to enhance user comfort and adherence to treatment.
Key points of interest for investors:
- High patient preference:
92.6% of experienced CPAP users preferred AirTouch N30i for long-term use - Aesthetic appeal:
96.7% rated the mask as appealing or very appealing - Market potential: Sleep apnea affects over 54 million Americans and nearly 1 billion people worldwide
While this product launch is promising, its impact on ResMed's financials will depend on market adoption rates and pricing strategy. The innovative design could potentially increase ResMed's market share in the competitive CPAP mask segment, but concrete sales figures will be needed to assess its true impact on the company's bottom line.
The launch of AirTouch N30i positions ResMed to potentially capture a larger share of the growing sleep apnea market. With nearly 1 billion people worldwide affected by sleep apnea, there's significant room for market expansion. The product's focus on comfort and aesthetics addresses key barriers to CPAP therapy adoption and adherence.
Market implications:
- Differentiation: The fabric-wrapped design sets AirTouch N30i apart in a crowded market
- Expanded user base: Improved comfort may attract new users and retain existing ones
- Potential for premium pricing: Enhanced features could justify higher price points
However, the impact on ResMed's market position will depend on factors such as reimbursement policies, competitive responses and the product's performance in real-world settings. The October 28, 2024 U.S. launch date gives ResMed time to build anticipation and prepare for a strong market entry. Investors should monitor initial sales data and user feedback post-launch to gauge the product's market reception and potential long-term impact on ResMed's revenue growth.
The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up design.
Sleep apnea affects more than 54 million people in the United States and nearly one billion people worldwide1. This chronic sleep-related breathing disorder can impair daily functioning and significantly increase the risk of serious comorbidities such as hypertension, diabetes, cardiovascular disease, and stroke2.
Innovative AirTouch N30i Designed to Deliver Exceptional Comfort for a More Natural Sleep Experience
As a global leader in sleep health, ResMed designs life-changing health technologies that people love, including the AirTouch N30i, designed to make it easier for people to start and stick with CPAP therapy. Building upon ResMed’s innovation and experience in developing high-performance masks, the AirTouch N30i combines softness, breathability, and a high-performance seal to deliver exceptional comfort in a nasal mask.
In a multi-center study with experienced CPAP users,
“As a global leader in sleep health and CPAP therapy, millions of people trust ResMed’s devices to help them sleep better and live healthier lives,” said Justin Leong, ResMed chief product officer. “We are excited to introduce the AirTouch N30i, a mask that redefines comfort with its soft, natural feel and sleek, modern design. It sets a new standard in CPAP masks, helping more people stay committed to their therapy and achieve better sleep while offering a refined aesthetic that is as pleasing to look at as it is to wear.”
Key Features of the AirTouch N30i
- Extraordinary comfort –The new ComfiSoft™ cushion and fabric-wrapped frame incorporate a fabric seal design with fabric coated over silicone. This innovative design creates maximum comfort while maintaining ResMed’s excellence in mask seal.
- Breakthrough innovation – By incorporating advanced technology into a compact, visually appealing design, we’ve pushed the boundaries of textile and manufacturing innovation to deliver superior performance, durability, and comfort.
- Comforting familiarity – Building on the award-winning AirFit N30i, the AirTouch N30i offers a customized fit using thousands of digital biomarkers. Available in three cushion sizes—Small, Medium, and Large—and two frame sizes: Small and Standard, this mask is designed to enable a tailored and comfortable fit.
The AirTouch N30i will be available in the U.S. beginning the week of October 28, 2024. For more information, visit ResMed.com/ProductUpdate.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we help improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For Media:
Rebecca Ehlinger-Janzon
news@resmed.com
(760) 496-8320
TEAM LEWIS
ResMedUS@teamlewis.com
For Investors:
Investorrelations@resmed.com
(858) 836-5000
1 Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698.
2 Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nature Reviews Disease Primers. 2015;1:15015.
3 Pablo M et al. Sleep 2024; 47 (Supplement_1): A248
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99cc85b5-26ce-456c-bad2-680075ea40d5
FAQ
What is the new CPAP mask launched by ResMed (RMD) called?
When will the AirTouch N30i be available in the United States?
What are the key features of ResMed's (RMD) new AirTouch N30i CPAP mask?
How did users rate the AirTouch N30i in ResMed's (RMD) multi-center study?
